Kyle Bass talks US drug patents and his fight to get rid of bad patents, and his strategy of shorting companies that have ‘bad’ patents or patents that never should have been filed.
When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.
Our Editorial Standards
At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.
Sheeraz Raza
Sheeraz is our COO (Chief - Operations), his primary duty is curating and editing of ValueWalk. He is main reason behind the rapid growth of the business. Sheeraz previously ran a taxation firm. He is an expert in technology, he has over 5.5 years of design, development and roll-out experience for SEO and SEM. - Email: sraza(at)www.valuewalk.com
Sheeraz is our COO (Chief - Operations), his primary duty is curating and editing of ValueWalk. He is main reason behind the rapid growth of the business. Sheeraz previously ran a taxation firm. He is an expert in technology, he has over 5.5 years of design, development and roll-out experience for SEO and SEM. - Email: sraza(at)www.valuewalk.com
Related news
Must Read
How to Invest in Stocks in 2024 – Beginner’s Guide
Investing in stocks can be a great way to improve your overall wealth – but...